Immune control of HIV-1 reservoirs

Current Opinion in HIV and AIDS

Volumn 8, Issue 3, 2013, Pages 204-210

  Autran, Brigitte ^a   Descours, Benjamin ^a   Bacchus, Charline ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

anti HIV CD8 T cells; HIV 1; immune control; innate immunity; reservoirs

Indexed keywords

CD4 ANTIGEN; INTERFERON;

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL DEATH; CELL PROLIFERATION; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; HELPER CELL; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE GENE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RESERVOIR; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE;

DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS REPLICATION;

EID: 84876420937     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835fe6d2     Document Type: Review

References (58)

1. Autran B, Descours B, Avettand-Fenoel V, et al. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.
2. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
3. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011; 25:885-897.
4. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
5. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-180.
6. Katlama C, Deeks SG, Autran B, et al. Barriers to a cure: new concepts in targeting and eradicating HIV-1 reservoirs. Lancet 2013 (in press).
7. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-657.
8. Baldauf HM, Pan X, Erikson E, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 2012; 18:1682-1687.
9. Cameron PU, Saleh S, Sallmann G, et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci USA 2010; 107:16934-16939.
10. Chege D, Sheth PM, Kain T, et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 2011; 25:741-749.
11. Saidi H, Carbonneil C, Magri G, et al. Differential modulation of CCR5-tropic human immunodeficiency virus-1 transfer from macrophages towards T cells under interleukin-4/interleukin-13 microenvironment. Hum Immunol 2010; 71:1-13.
12. Katsikis PD, Mueller YM, Villinger F. The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog 2011; 7:e1002055.
13. Lu J, Pan Q, Rong L, et al. The IFITM proteins inhibit HIV-1 infection. J Virol 2011; 85:2126-2137.
14. Machmach K, Leal M, Gras C, et al. Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol 2012; 86:4245-4252.
15. Giri MS, Nebozyhn M, Raymond A, et al. Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus-and host-mediated apoptosis resistance. J Immunol 2009; 182:4459-4470.
16. Iwasaki A. Innate immune recognition of HIV-1. Immunity 2012; 37:389-398.
17. Kornfeld C, Ploquin MJ, Pandrea I, et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005; 115:1082-1091.
18. Lederer S, Favre D, Walters KA, et al. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog 2009; 5:e1000296.
19. Ganesan A, Chattopadhyay PK, Brodie TM, et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis 2010; 201:272-284.
20. Bacchus C, Cheret A, Avettand-Fenoël V, et al. Early establishment of the HIV-1 reservoir and skewed immune homeostasis driven by a single viral cluster within a month from HIV-1 infection [Poster]. In: Presented in The 52nd ICAAC 2012 conference took place in San Francisco on 9-12 September 2012; USA: American Society for Microbiology.
21. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
22. Descours B, Avettand-Fenoel V, Blanc C, et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012; 54:1495-1503.
23. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. PLoS Path 2013 (in press).
24. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128-137.
25. Cohen J. The emerging race to cure HIV infections. Science 2011; 332:784-785; 787-9.
26. Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2012; 210:143-156.
27. Descours B, Lambert-Niclot S, Mory B, et al. Direct quantification of cell associated HIV-DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated patients. J Acquir Immune Defic Syndr 2012; 62:255-259.
28. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive anti-retroviral therapy. J Infect Dis 2010; 202:1553-1561.
29. Shankar EM, Che KF, Messmer D, et al. Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells. Mol Med 2011; 17:229-240.
30. Dalmasso C, Carpentier W, Meyer L, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 2008; 3:e3907.
31. Guergnon J, Dalmasso C, Broet P, et al. Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infection. J Infect Dis 2012; 205:718-724.
32. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
33. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947.
34. + T-cell polyfunctionality and HIV-suppressive activity. Blood 2009; 113:6351-6360.
35. Martinez V, Costagliola D, Bonduelle O, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005; 191:2053-2063.
36. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-1021.
37. Saez-Cirion A, Sinet M, Shin SY, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009; 182:7828-7837.
38. Xie J, Lu W, Samri A, et al. Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control. AIDS 2010; 24:2323-2329.
39. + T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog 2010; 6:e1000780.
40. Shacklett BL. Ferre AL: mucosal immunity in HIV controllers: the right place at the right time. Curr Opin HIV AIDS 2011; 6:202-207.
41. + T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 2008; 1:475-488.
42. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
43. Ngo-Giang-Huong N, Candotti D, Goubar A, et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 2001; 17:1435-1446.
44. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117:2791-2799.
45. Ho J, Moir S, Kulik L, et al. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol 2007; 178:6968-6974.
46. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010; 24:614-617.
47. Boulassel MR, Chomont N, Pai NP, et al. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol 2012; 53:29-32.
48. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; doi:10.1093/jac/dks533.
49. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immuno-virologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
50. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24:2803-2808.
51. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106:9403-9408.
52. Autran B, Carcelain G, Combadiere B, et al. Therapeutic vaccines for chronic infections. Science 2004; 305:205-208.
53. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501.
54. Persaud D, Luzuriaga K, Ziemniak C, et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS 2011; 25:2227-2234.
55. Autran B, Murphy RL, Costagliola D, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313-1322.
56. Renga B, Francisci D, D'Amore C, et al. The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent pro-inflammatory phenotype in monocytes. PLoS One 2012; 7:e35924.
57. Shete A, Thakar M, Singh DP, et al. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations. AIDS Res Hum Retroviruses 2012; 28:835-843.
58. Patterson LJ, Kuate S, Daltabuit-Test M, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 2012; 19:629-637.